

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
3 July 2008 (03.07.2008)

PCT

(10) International Publication Number
WO 2008/077639 A1

(51) International Patent Classification:

C07D 213/79 (2006.01) **A61K 31/465** (2006.01)
C07D 213/80 (2006.01) **A61P 35/00** (2006.01)

(21) International Application Number:

PCT/EP2007/011401

(22) International Filing Date:

21 December 2007 (21.12.2007)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

P200603250 22 December 2006 (22.12.2006) ES
P200701086 23 April 2007 (23.04.2007) ES

(71) Applicant (for all designated States except US): **LABORATORIOS ALMIRALL, S.A.** [ES/ES]; Ronda del General Mitre, 151, E-08022 Barcelona (ES).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **CASTRO PALOMINO LARIA, Julio Cesar** [DE/ES]; c/ Enrique Granados 29, 4º, E-08330 Premià De Mar (Barcelona) (ES). **ERRA SOLA, Montserrat** [ES/ES]; Riera Blanca

46, Atico 1a, Esc. A, E-08903 L' Hospitalet (Barcelona) (ES). **LOZOYA TORIBIO, Maria Estrella** [ES/ES]; C/ Brodadores, 6F, E-08100 Mollet del Valles (Barcelona) (ES). **NAVARRO ROMERO, Eloisa** [ES/ES]; c/Comte d'Urgell 20, 1º 2ª, E-08011 Barcelona (ES).


(74) Agent: **SRINIVASAN, RC**; J.A. Kemp & Co., 14 South Square, Gray's Inn, London WC1R 5JJ (GB).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL,

[Continued on next page]

(54) Title: AMINO NICOTINIC AND ISONICOTINIC ACID DERIVATIVES AS DHODH INHIBITORS



(57) Abstract: A compound of formula (I) wherein : - one of the groups G^1 represents a nitrogen atom or a group CR^c and the other represents a group CR^c ; - G^2 represents a nitrogen atom or a group CR^d ; - R^1 represents a group selected from hydrogen atoms, halogen atoms, C_{1-4} alkyl groups which may be optionally substituted by 1, 2 or 3 substituents selected from halogen atoms and

hydroxy groups, and C_{3-8} cycloalkyl groups which may be optionally substituted by 1, 2 or 3 substituents selected from halogen atoms and hydroxy groups; - R^2 represents a group selected from hydrogen atoms, halogen atoms, hydroxyl groups, C_{1-4} alkyl groups which may be optionally substituted by 1, 2 or 3 substituents selected from halogen atoms and hydroxy groups, C_{1-4} alkoxy groups which may be optionally substituted by 1, 2 or 3 substituents selected from halogen atoms and hydroxy groups, and C_{3-8} cycloalkyl groups which may be optionally substituted by 1, 2 or 3 substituents selected from halogen atoms and hydroxy groups; - R^a , R^b and R^c independently represent groups selected from hydrogen atoms, halogen atoms, C_{1-4} alkyl groups which may be optionally substituted by 1, 2 or 3 substituents selected from halogen atoms and hydroxy groups, and C_{1-4} alkoxy groups which may be optionally substituted by 1, 2 or 3 substituents selected from halogen atoms and hydroxy groups; - R^d represents a group selected from hydrogen atoms, halogen atoms, hydroxyl groups, C_{1-4} alkyl groups which may be optionally substituted by 1, 2 or 3 substituents selected from halogen atoms and hydroxy groups, and C_{1-4} alkoxy groups which may be optionally substituted by 1, 2 or 3 substituents selected from halogen atoms and hydroxy groups; - one of the groups G^3 and G^4 is a nitrogen atom and the other is a CH group; - M is a hydrogen atom or an pharmaceutically acceptable cation with the proviso that, when at least one of the groups R^a and R^b represent a hydrogen atom and G^2 is a group CR^d , then R^d represents a groups selected from C_{1-4} alkoxy groups which may be optionally substituted by 1, 2 or 3 substituents selected from halogen atoms and hydroxy groups, C_{3-8} cycloalkoxy groups which may be optionally substituted by 1, 2 or 3 substituents selected from halogen atoms and hydroxy groups; and the pharmaceutically acceptable salts and N-oxides thereof.

WO 2008/077639 A1



PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM,
GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

— *before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments*

Published:

— *with international search report*